TRANG HUYNH, FNP
Family Nurse Practitioner · SUGARLAND, TX
Individual Active NPI 1518212802
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 648 | 264,945 | $20,096,569 | $5,477,297 | $4,359,804 |
| 2023 | 569 | 157,015 | $15,712,640 | $4,640,089 | $3,687,559 |
| 2022 | 501 | 115,054 | $13,313,889 | $3,949,722 | $3,146,739 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J0174 | Injection, lecanemab-irmb, 1 mg | 83,530 | $1 | $1 |
| J3111 | Injection, romosozumab-aqqg, 1 mg | 53,970 | $11 | $8 |
| J0897 | Injection, denosumab, 1 mg | 17,280 | $25 | $20 |
| J1756 | Injection, iron sucrose, 1 mg | 7,200 | $0 | $0 |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 6,900 | $22 | $17 |
| J3245 | Injection, tildrakizumab, 1 mg | 4,800 | $135 | $107 |
| J2182 | Injection, mepolizumab, 1 mg | 4,700 | $30 | $24 |
| J2357 | Injection, omalizumab, 5 mg | 3,210 | $37 | $30 |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 2,370 | $31 | $25 |
| J9312 | Injection, rituximab, 10 mg | 1,740 | $68 | $55 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 1,480 | $0 | $0 |
| J0517 | Injection, benralizumab, 1 mg | 1,350 | $165 | $131 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Family Nurse Practitioner | 363LF0000X | ✓ | AP122038 | TX |
| Family Nurse Practitioner | 363LF0000X | 772038 | TX |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- No
Other Family Nurse Practitioner providers in Texas
- NPI 1689692618
- NPI 1225695737
- NPI 1710453014
- NPI 1063301687
- NPI 1730728403
- NPI 1578158689
- NPI 1942417472
- NPI 1841040912
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.